These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35378298)

  • 1. Targeted protein degraders march towards the clinic for neurodegenerative diseases.
    Kumar D; Hassan MI
    Ageing Res Rev; 2022 Jun; 78():101616. PubMed ID: 35378298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research.
    Li X; Liu Q; Xie X; Peng C; Pang Q; Liu B; Han B
    J Med Chem; 2023 Feb; 66(3):1700-1711. PubMed ID: 36716420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications].
    Reboud-Ravaux M
    Biol Aujourdhui; 2024; 218(1-2):41-54. PubMed ID: 39007776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases.
    Hyun S; Shin D
    Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34202541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.
    Fang Y; Wang J; Zhao M; Zheng Q; Ren C; Wang Y; Zhang J
    J Med Chem; 2022 Sep; 65(17):11454-11477. PubMed ID: 36006861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research progress of PROTACs for neurodegenerative diseases therapy.
    Cai Z; Yang Z; Li H; Fang Y
    Bioorg Chem; 2024 Jun; 147():107386. PubMed ID: 38643565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
    Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted protein degradation and drug discovery.
    Naito M
    J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress of small molecules for targeted protein degradation: PROTACs and other technologies.
    Zhao HY; Xin M; Zhang SQ
    Drug Dev Res; 2023 Apr; 84(2):337-394. PubMed ID: 36606428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects.
    Tsukumo Y; Tsuji G; Yokoo H; Shibata N; Ohoka N; Demizu Y; Naito M
    Methods Mol Biol; 2021; 2365():331-347. PubMed ID: 34432253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders.
    Tomoshige S; Ishikawa M
    Angew Chem Int Ed Engl; 2021 Feb; 60(7):3346-3354. PubMed ID: 32410219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chasing molecular glue degraders: screening approaches.
    Domostegui A; Nieto-Barrado L; Perez-Lopez C; Mayor-Ruiz C
    Chem Soc Rev; 2022 Jul; 51(13):5498-5517. PubMed ID: 35723413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety.
    Shoda T; Ohoka N; Tsuji G; Fujisato T; Inoue H; Demizu Y; Naito M; Kurihara M
    Pharmaceuticals (Basel); 2020 Feb; 13(3):. PubMed ID: 32106507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer.
    Chen QH; Munoz E; Ashong D
    Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degraders in epigenetic therapy: PROTACs and beyond.
    Dai XJ; Ji SK; Fu MJ; Liu GZ; Liu HM; Wang SP; Shen L; Wang N; Herdewijn P; Zheng YC; Wang SQ; Chen XB
    Theranostics; 2024; 14(4):1464-1499. PubMed ID: 38389844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SNIPERs-Hijacking IAP activity to induce protein degradation.
    Naito M; Ohoka N; Shibata N
    Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery.
    Dong G; Ding Y; He S; Sheng C
    J Med Chem; 2021 Aug; 64(15):10606-10620. PubMed ID: 34319094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Chimeric Molecules That Degrade the Estrogen Receptor Using Decoy Oligonucleotide Ligands.
    Naganuma M; Ohoka N; Tsuji G; Tsujimura H; Matsuno K; Inoue T; Naito M; Demizu Y
    ACS Med Chem Lett; 2022 Jan; 13(1):134-139. PubMed ID: 35059133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
    Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
    Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.